跳轉至內容
Merck
全部照片(1)

重要文件

SML0132

Sigma-Aldrich

醋酸兰瑞肽

≥98% (HPLC)

同義詞:

3-(2-萘基)-D-丙氨酰基-L-半胱氨酰基-L-酪氨酸-D-色氨酸-L-赖氨酰基-L-戊酰基-L-半胱氨酰-L-苏氨酸酰胺环状(2→7)-乙酸二硫, BIM-23014C, 醋酸血管肽素

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C54H69N11O10S2 · xC2H4O2
CAS號碼:
分子量::
1096.32 (free base basis)
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.25

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to off-white

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

CC(O)=O.CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@H](N)Cc5ccc6ccccc6c5

InChI

1S/C54H69N11O10S2.C2H4O2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55;1-2(3)4/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74);1H3,(H,3,4)/t30-,38-,40+,41+,42-,43+,44?,45+,46+;/m1./s1

InChI 密鑰

DEXPIBGCLCPUHE-HPDHVNDUSA-N

應用

乙酸兰瑞肽已被用作抑制剂,以测试野生型小鼠中生长激素/甲状腺激素信号转导对硫化氢调节的可变性。

生化/生理作用

醋酸兰瑞肽是一种生长抑素类似物,是生长抑素受体SRIF-1 sst2亚型的选择性激动剂,对sst2的结合亲和力为0.8 nM,对sst5的结合亲和力为5.2 nM,对sst3的结合亲和力为100 nM,对于SRIF-2亚型sst1和sst4受体的结合亲和力为1000 nM以上。它在临床上可用于肢端肥大症和神经内分泌肿瘤所引起的症状的治疗,并且在最近的研究中还可以用于抑制肿瘤的生长,并显示出对非内分泌肿瘤的活性。

象形圖

Health hazard

訊號詞

Warning

危險聲明

防範說明

危險分類

Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Lucas Sidéris et al.
The oncologist, 17(6), 747-755 (2012-05-26)
For decades, somatostatin analogs (including octreotide and lanreotide) have been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with secretory neuroendocrine tumors (NETs). Recently, it has been suggested that somatostatin analogs may provide direct and indirect
Nancy M Gardner-Roehnelt
Clinical journal of oncology nursing, 16(1), 56-64 (2012-02-03)
Although neuroendocrine tumors (NETs) have been recognized as a family of complex malignancies since 1907, major progress has been made only in the past 20 years in understanding and managing the disease. The detection and reported incidence of NETs have
Christos Toumpanakis et al.
Seminars in oncology, 40(1), 56-68 (2013-02-09)
Somatostatin analogs (SA) are the standard of care for controlling symptoms of patients with functional gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). SA control symptoms in more than 70% of patients with carcinoid syndrome. Similar results are obtained in patients with functional, hormone-secreting
Martyn E Caplin et al.
The New England journal of medicine, 371(3), 224-233 (2014-07-12)
Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced
Omid Fotouhi et al.
The Journal of clinical endocrinology and metabolism, 101(10), 3616-3627 (2016-07-28)
Somatostatin analogs are established in the treatment of neuroendocrine tumors (NETs) including small intestinal NET; however, the molecular mechanisms are not well known. Here, we examined the direct effects of lanreotide in NET cell line models. The cell lines HC45

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務